Choose laser treatment from the angle anatomy, pressure target, visual potential and previous treatment. Improving an anatomical feature or lowering pressure does not by itself establish better vision or quality of life.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Select the target before selecting the laser
Laser can be initial treatment, an adjunct or a bridge to further surgery. Distinguish trabecular outflow treatment from relief of pupillary block and treatment of the ciliary body; the word laser alone does not identify an indication. 1
Document gonioscopy, pigmentation, baseline pressure, target pressure, optic nerve and field damage, current medication and previous procedures. Check whether the intended structure is visible and accessible. The lecture's demand for gonioscopy is a practical assessment principle, not proof that one examination makes every glaucoma mechanism certain. 1
A high presenting pressure or advanced damage may require prompt additional treatment. The original >35 mmHg laser threshold is not a universal rule for forcing surgery. Estimate how much reduction is needed and whether a delayed laser response is acceptable; EAGLE's ≥30 mmHg inclusion criterion concerns a different population and intervention. 1
02ALT and SLT: mechanism, parameters and response
Argon laser trabeculoplasty (ALT) produces thermal effects in the trabecular meshwork. Selective laser trabeculoplasty (SLT) uses short pulses that preferentially target pigmented cells and provoke a biological remodelling response. The lecture's word regenerative is a mechanistic shorthand; it does not establish nerve regeneration or absence of tissue injury. The source lecture invokes cytokines, macrophage activity and extracellular-matrix remodelling as its explanatory model; the exact mechanistic source remains to be verified. 1 18
The original comparison gives an ALT spot diameter of 50 µm and an SLT spot diameter of 400 µm. EGS 6 lists these values and describes SLT as a frequency-doubled 532 nm Nd:YAG laser with 3 ns pulses. These are procedure characteristics, not interchangeable settings between devices. 1
The lecture quotes SLT energy 0.4–1.4 mJ, treatment over 180° or 360° and titration to tiny bubbles. EGS 6 instead lists 0.4–1.2 mJ and permits consideration of an initial 180° treatment in heavily pigmented angles. Preserve the source difference; adjust treatment to the device and tissue response rather than copying either range as an operative protocol. 1
SLT can be considered in suitable primary open-angle glaucoma (POAG), pseudoexfoliative glaucoma and ocular hypertension (OHT). Pigmentary disease needs particular caution about pigmentation and pressure spikes. NICE excludes pigment dispersion syndrome from its routine first-line 360° SLT recommendation; this is not the same as declaring every pigmentary case absolutely unsuitable. 1 2
The lecture estimates a 20–25% pressure reduction and about 20% non-response. EGS 6 describes initial response in 80–85% of treated eyes, with average reduction 20–25% or 4–9 mmHg. Definitions, baseline pressure and prior medication affect these estimates; none is an individual success guarantee. 1
The original 4–6 week response estimate should not delay early safety checks. EGS 6 recommends assessing efficacy around 6–8 weeks, while checking pressure earlier. Effect can diminish, and repeat SLT or additional treatment may be needed. Prior SLT does not automatically preclude later filtering surgery, but future suitability still requires assessment. 1
03Read the SLT and DSLT comparisons correctly
LiGHT was a multicentre randomised comparison of initial SLT versus drops in treatment-naive OAG/OHT. At 6 years, 524 participants completed follow-up, 73% of those initially randomised. EQ-5D, GUI and GQL-15 did not differ significantly; the glaucoma symptom score favoured SLT. Do not rewrite this as general quality-of-life superiority. 3 4
The original report gives 69.8% of SLT eyes at target without medical or surgical treatment, and progression in 19.6% versus 26.8% with initial drops. Its 2025 corrigendum changes incisional glaucoma surgery counts to 16 SLT versus 33 drops eyes (p=0.001), replacing the earlier 13 versus 32 trabeculectomy wording. Cataract surgery counts remain 57 versus 95 (p=0.03). 3 4
Repeat SLT and treatment switching were allowed in the extension. Attrition and knowledge of treatment constrain interpretation; surgical endpoints are different from patient-reported outcomes. Cost-effectiveness depends on the health system and time horizon. The corrected surgical figures are identified in the publisher's indexed correction excerpt; the complete correction tables still require direct inspection before final approval. 3 4
Direct selective laser trabeculoplasty (DSLT) automates translimbal treatment without a gonioscopy contact lens. The original 360° in approximately 20 seconds claim describes treatment delivery, not total visit time, proven comfort superiority or long-term effectiveness. Diagnostic angle assessment remains necessary even when delivery is contactless. 5
GLAUrious randomised 192 adults aged ≥40 years with OAG/OHT and washout pressure 22–35 mmHg. At 6 months, the protocol-compliant analysis of 156 participants found reductions of 5.5 versus 6.2 mmHg for DSLT versus SLT. The difference was −0.7 mmHg (95% CI −2.2 to 0.8), crossing the −1.95 mmHg noninferiority margin; the primary noninferiority test did not pass. 5
Exploratory 12-month results used nonwashout pressure and cannot replace the unsuccessful primary endpoint. Protocol exclusions, short follow-up and commercial involvement matter. Similar pressure reduction or broadly similar reported safety is not proof of equivalence, lifetime benefit or universal DSLT superiority. 5
04LPI and iridoplasty: anatomy and residual closure
Laser peripheral iridotomy (LPI) connects the posterior and anterior chambers to relieve pupillary block. It is relevant to acute angle closure and selected angle-closure disease or higher-risk suspects. Acute pain, redness, reduced vision, haloes or nausea require urgent assessment; LPI is not a substitute for initial pressure control when the cornea or clinical state prevents safe treatment. 1
A patent LPI does not necessarily remove lens crowding, peripheral anterior synechiae or plateau iris. It may help identify a residual non-pupillary-block mechanism, but it does not independently diagnose plateau iris or cure all angle closure. Reassess gonioscopy and pressure after the intervention. 1
Dysphotopsia means disturbing light phenomena such as lines, glare or ghost images. The lecture's tear-film meniscus/prism explanation is a proposed mechanism, not the sole proven cause. Superior placement is not universally replaced by temporal placement: anatomy, vessels, eyelid coverage and laser access matter, and comparative evidence does not establish one location as best for everyone. 1 6
Potential LPI complications include pressure spikes, bleeding, inflammation, lens injury and visual symptoms; endothelial or corneal injury is also relevant to laser planning. Confirm patency rather than relying solely on red reflex transillumination. EGS 6 advises a pressure check after 1–3 hours and later gonioscopic reassessment; adapt follow-up to the individual risk. 1
Peripheral laser iridoplasty uses peripheral iris contraction to widen an appositionally closed angle, including selected plateau-iris situations despite a patent LPI. An anatomical opening is not proof of sustained pressure or visual benefit. Cochrane's 2021 review of 4 RCTs did not establish a clinical advantage in chronic angle closure; evidence certainty was limited. 1 7
Iridoplasty can cause inflammation, pressure elevation, corneal endothelial burns, synechiae, iris atrophy or persistent pupil change. Select the mechanism and discuss alternatives. Do not turn a discussion of rescue treatment for an acute episode into a routine recommendation for every chronically narrow angle. 1
05EAGLE and ZAP answer different angle-closure questions
EAGLE randomised 419 people aged ≥50 years without cataract to clear-lens extraction (CLE) or LPI-based standard care with medication. Eligibility was newly diagnosed primary angle closure (PAC) with pressure ≥30 mmHg, or primary angle-closure glaucoma (PACG). The original >50 and >30 wording misses the inclusive boundaries and the separate PACG route. 8
At 36 months, CLE improved EQ-5D by 0.052 (95% CI 0.015–0.088) and lowered pressure by 1.18 mmHg more (95% CI 0.38–1.99). Health-status data were complete for 84% and pressure data for 87%. These modest average differences, surgical risks and population restrictions must accompany the benefit; this is not a general pressure threshold for SLT or an instruction to remove every clear lens. 8
ZAP enrolled 889 Chinese participants aged 50–70 years with bilateral primary angle-closure suspect (PACS); one eye received LPI and its fellow eye was untreated. At 72 months, the composite PAC endpoint occurred in 19 versus 36 eyes: 4.19 versus 7.97 events per 1000 eye-years, HR 0.53 (95% CI 0.30–0.92). The endpoint included pressure elevation, synechiae or acute closure, not just acute attacks or visual loss. 9
The original 4/1000 to 2/1000 statement lacks the correct endpoint and time denominator. In the 14-year extension, 33 treated versus 105 control eyes reached the composite endpoint, HR 0.31 (95% CI 0.21–0.46); acute attacks numbered 1 versus 5. Loss to follow-up was substantial: 390 versus 388 eyes. This is extended follow-up of the same cohort, not independent replication. 9 10
Low absolute event rates in community-screened PACS do not mean zero risk in a symptomatic or higher-risk patient. Balance anatomy, exposure to dilation, ability to obtain urgent care and the individual clinical context. ZAP does not support blanket LPI for every suspect or blanket avoidance in high-risk angle closure. 1 9 10
06CPC: distinguish modes, populations and meaningful outcomes
Cyclophotocoagulation (CPC) treats the ciliary body to reduce pressure. Transscleral diode treatment commonly uses 810 nm; continuous-wave, slow-coagulation, micropulse and endoscopic approaches have different delivery patterns and evidence. EGS 6 includes refractory disease and situations where filtration or drainage surgery has failed, is likely to fail or is not feasible. CPC is not universally confined to blind painful eyes. 1
Micropulse intersperses energy delivery with rest periods. A tissue-sparing rationale does not establish freedom from inflammation, hypotony, visual loss or retreatment. Preserve the lecture's cyclomodulation terminology as an explanatory model; use device-specific guidance and do not publish unverified energy escalation as an operative instruction. 1 11
Aquino's exploratory randomised study enrolled 48 patients with refractory end-stage glaucoma. Success with micropulse versus continuous-wave CPC was 75% versus 29% at 12 months, but 52% versus 30% at 18 months (p=0.13). Success required pressure 6–21 mmHg and ≥30% reduction, with or without drops. The reported complication rate favoured micropulse; small numbers and limited follow-up preclude a universal safety ranking. 11
The 2019 Cochrane review found insufficient comparative evidence to select a universally best cyclodestructive procedure. The lecture's claim of faster field loss than after trabeculectomy has no identified matched comparison here. Preserve that question in the correction record without teaching it as fact. Hypotony, phthisis, persistent inflammation and vision loss remain important; sympathetic ophthalmia is a reported rare complication, without a universal rate established here. 1 12 13
Do not extrapolate adult findings to childhood glaucoma. Wang's 2024 retrospective two-centre paediatric comparison reported 1-year success in 7/26 micropulse versus 13/30 continuous-wave eyes, with survival comparison p=0.03. Selection, variable settings, eye dependence and absent functional outcomes limit causal interpretation. The Cornelia-de-Lange teaching case discussed in the separate childhood-glaucoma lecture is an individual anaesthetic-risk decision, not evidence of comparative efficacy. 14
07Perioperative protection, guidance and follow-up
Perioperative pressure-spike protection may include an alpha-2 agonist such as apraclonidine or brimonidine, or an alternative chosen for the patient and procedure. Check product-specific contraindications, age, systemic disease and interactions. This is not a universal prescription or paediatric dosing instruction. 1
The original rule of mandatory steroid for at least 1 week after every laser is too broad. EGS 6 states that anti-inflammatory drops after SLT may be used for 4–7 days but are often unnecessary; LPI and CPC have different aftercare needs. SALT used 5 days of drops and found greater pressure reduction at 12 weeks with anti-inflammatory treatment, whereas an earlier masked RCT did not show a pressure advantage. Neither establishes a universal regimen. 1 15 16
The original unspecified German S3 laser-guideline attribution is unverified. The identified DOG/BVA AWMF 045-015 document is an S2e risk-factor guideline, not a comprehensive laser-treatment protocol. Keep its scope separate from EGS guidance, NICE recommendations, AAO source records and individual trial results. 17
Check pressure, inflammation, symptoms, medication use and the procedure-specific anatomical result. Early pressure surveillance and later efficacy assessment answer different questions. Continue optic nerve and field monitoring even after an apparently successful laser; pressure control does not restore established glaucomatous nerve loss. 1
08Compare procedures and practise recall
The 6 comparison rows orient the reader; the lecture and cited limitations remain necessary. Recall questions are voluntary and are not a validated clinical competency assessment. 1
| Procedure | Target and teaching parameters | Clinical place | Evidence boundary | Risks and exceptions |
|---|---|---|---|---|
| SLT | Trabecular outflow; 400 µm; average 20–25% reduction | Initial or adjunct treatment in selected open-angle disease | LiGHT disease control differs from general QoL benefit; repeat treatment allowed | Non-response, pressure spikes, inflammation; response estimates and timing vary |
| DSLT | Automated contactless translimbal treatment; lecture: 360° in about 20 seconds | Alternative delivery approach after assessment | GLAUrious did not meet its 6-month primary noninferiority endpoint | No universal comfort, safety or long-term superiority claim |
| ALT | Thermal trabecular effects; 50 µm | Established procedure; SLT often preferred | Comparable pressure lowering does not establish identical tissue effects | Synechiae, thermal changes and reduced effect over time |
| LPI | Relief of pupillary block | Angle-closure treatment or selected prophylaxis | EAGLE PAC/PACG differs from ZAP PACS; no 2/1000 universal risk | Pressure spikes, bleeding, dysphotopsia, lens/corneal injury; residual closure |
| CPC | Ciliary body; distinguish continuous-wave, slow-coagulation, micropulse and endoscopic delivery | Refractory disease or selected alternatives; not universally last resort | Small and heterogeneous comparisons; pressure success is not visual preservation | Hypotony, phthisis, inflammation, vision loss and retreatment; rare sympathetic ophthalmia reported |
| Iridoplasty | Peripheral iris contraction | Selected persistent appositional closure despite patent LPI | Anatomical widening is not proven long-term clinical benefit | Inflammation, pressure spikes, synechiae and iris/corneal injury |
What are the main learning points?
Choose laser treatment from the angle anatomy, pressure target, visual potential and previous treatment. Improving an anatomical feature or lowering pressure does not by itself establish better vision or quality of life.
When is assessment urgent?
Seek urgent ophthalmic assessment for severe pain, marked loss of vision, increasing redness or haloes with headache/nausea, including after laser treatment. Mild irritation should not progressively worsen.
References and access status
- 1EGS Terminology and Guidelines for Glaucoma, 6th edition (2025)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Local supplied PDF text inspected: laser sections pp 187–193, including extracted parameter tables; relevant document sections only, not the complete book or a new visual table appraisal. DOI 10.1136/bjophthalmol-2025-egsguidelines.
- 2NICE NG 81: Glaucoma, diagnosis and management
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Official indexed recommendation text inspected for first-line 360° SLT and exclusions. Direct full-page retrieval returned 403; complete guideline/evidence appendices not read in this pass.
- 3Gazzard et al. LiGHT six-year results (2023)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Full repository abstract inspected; full article/supplements not re-read in this pass. DOI 10.1016/j.ophtha.2022.09.009. Read with 2025 corrigendum; earlier surgery counts are superseded.
- 4LiGHT corrigendum (2025), DOI 10.1016/j.ophtha.2025.07.029
Historical 008-glaucoma-laser appraisal reused; not new full-source access. PubMed erratum record and publisher-indexed correction excerpt inspected. Direct publisher retrieval 403; complete pp 1323–1325/tables unread. Indexed excerpt corrects incisional surgery to 33 drops versus 16 SLT eyes, p=0.001; obtain full correction before final approval.
- 5Gazzard et al. GLAUrious (2025), DOI 10.1016/j.ophtha.2025.05.004
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Complete primary abstract directly inspected; main article, protocol details and supplements unread. Primary noninferiority endpoint not met; 12-month result exploratory.
- 6Dysphotopsia and location of laser iridotomy, systematic review (2024)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Indexed review abstract/results inspected, not complete full text. No universal location superiority inferred.
- 7Bayliss et al. Laser peripheral iridoplasty for chronic angle closure (2021)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Primary review's indexed abstract including conclusions inspected; complete review/appendices unread. DOI 10.1002/14651858.CD006746.pub4.
- 8Azuara-Blanco et al. EAGLE (2016)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Complete primary abstract directly read; main article and supplements unread. DOI 10.1016/S0140-6736(16)30956-4. Inclusion and missing-data limits retained.
- 9He et al. ZAP six-year trial (2019)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Publisher-indexed full abstract inspected, not complete article. DOI 10.1016/S0140-6736(18)32607-2. Composite endpoint and eye-year denominator retained.
- 10Yuan et al. ZAP fourteen-year extension (2023)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Complete indexed abstract inspected; direct retrieval gave incomplete page. Main article/supplement unread. Same cohort as original ZAP, with substantial loss to follow-up.
- 11Aquino et al. Micropulse versus continuous-wave CPC (2015)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Complete indexed primary abstract inspected; full text unread. DOI 10.1111/ceo.12360. Exploratory end-stage adult population.
- 12Chen et al. Cyclodestructive procedures for refractory glaucoma (2019)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Indexed review abstract and accessible report portions inspected; complete review/appendices not inspected. Search ended 21 September 2018. DOI 10.1002/14651858.CD012223.pub2.
- 13Cochrane: Cyclodestructive procedures for non-refractory glaucoma (2018)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Indexed report passage on rare reported sympathetic ophthalmia inspected; not a complete review or a universal risk estimate.
- 14Wang et al. Paediatric micropulse versus continuous-wave CPC (2024)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Source appraisal carried forward from review 007 main-narrative/Table 1 inspection; supplements and figure pixels unread. Not newly re-read here. Selection, numerical discrepancies and functional-outcome limits remain in linked review 007 follow-up.
- 15Groth et al. SALT trial (2019)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Complete indexed primary abstract inspected; main text/supplements unread. DOI 10.1016/j.ophtha.2019.05.032. Small short-term trial, not universal postoperative prescribing.
- 16Jinapriya et al. Anti-inflammatory therapy after SLT (2014)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Complete primary abstract directly read; full article unread. DOI 10.1016/j.ophtha.2014.07.017. Different population/baseline pressure and endpoint from SALT.
- 17DOG/BVA AWMF 045-015, S2e risk factors for open-angle glaucoma (2024)
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Official indexed title, grade and scope inspected. Adult risk-factor guideline, not proof of an unspecified German S3 laser-treatment protocol; no new full-document reading claimed.
- 18Original laser lecture / NotebookLM-derived source representation
Historical 008-glaucoma-laser appraisal reused; not new full-source access. Complete existing German page and embedded Studio summary read. Original video, spoken transcript, images and slides not inspected. All original video links retained; the derivative summary does not establish exact spoken attribution.
- 19Immutable original export; own glaucoma laser lecture; original settings/study claims archived
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
Original lecture link
For patients
Laser treatments act at different parts of the eye. Your team selects the procedure after assessing the drainage angle, pressure, optic nerve and previous treatment.
Many procedures are performed with local anaesthesia, but the method depends on the laser and the individual situation. Further drops or surgery may still be needed.
Attend the pressure and inflammation checks. Change existing drops only on your treating team's instructions. Later follow-up remains necessary even if the laser initially works well.
Seek urgent ophthalmic assessment for severe pain, marked loss of vision, increasing redness or haloes with headache/nausea, including after laser treatment. Mild irritation should not progressively worsen.